Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease | Zendy

Juhi Moon | Zendy; Robert H. Hyland | Zendy; Fangqiu Zhang | Zendy; Diana M. Brainard | Zendy; Sophie Lanzkron | Zendy; John G. McHutchison | Zendy; Mark Sulkowski | Zendy

Open Access

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease

Author(s) -

Juhi Moon,

Robert H. Hyland,

Fangqiu Zhang,

Diana M. Brainard,

Sophie Lanzkron,

John G. McHutchison,

Mark Sulkowski

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix441

Subject(s) - medicine , ledipasvir , sofosbuvir , ribavirin , anemia , hepatitis c , population , sickle cell anemia , disease , gastroenterology , immunology , chronic hepatitis , virus , environmental health

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research